Results 161 to 170 of about 35,846 (211)
Some of the next articles are maybe not open access.
Insulin, 2007
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases levels of active GLP-1. This increases insulin secretion and reduces glucagon secretion, thereby lowering glucose levels.
openaire +2 more sources
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases levels of active GLP-1. This increases insulin secretion and reduces glucagon secretion, thereby lowering glucose levels.
openaire +2 more sources
DPP-4 inhibitors and atherosclerosis: The promise
Atherosclerosis, 20130021-9150/$ e see front matter 2013 Elsevier Irela http://dx.doi.org/10.1016/j.atherosclerosis.2012.12.033 The major cause of mortality and morbidity in diabetes is cardiovascular disease (CVD). Novel therapies that have now been introduced for the treatment of diabetes includingmodulation of the Incretin axis with either glucagon like peptide-1 ...
Ishwarlal, Jialal, Mandeep, Bajaj
openaire +2 more sources
Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety, 2021Abstract:: Dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins belong to the class of incretin mimetics. These drugs have been available on the market for the management of type 2 diabetes mellitus (T2DM) for over a decade. Sitagliptin, linagliptin, vildagliptin, saxagliptin and alogliptin are widely available globally, whilst anagliptin ...
Nikhila A. Subrahmanyan +3 more
openaire +2 more sources
DPP-4 inhibitors: a patent review (2012 – 2014)
Expert Opinion on Therapeutic Patents, 2014Dipeptidyl peptidase 4 (DPP-4) is a serine protease, which catalyzes the hydrolytic process of the amide bond X-Ala or X-Pro at the N-terminus of peptides. This enzyme is involved in the degradation of two incretin hormones glucagon-like peptide-1 and glucose-dependent-insulinotropic polypeptide, which increase the production and release of insulin ...
COSTANTE, ROBERTO +4 more
openaire +3 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2015
Now seven compounds of DPP-4 inhibitor are available in Japan. They can be used in any stage of type 2 diabetes if the insulin secretion capacity is retained; first-line choice to third-line choice or combination with insulin therapy. There is no apparent difference in effect of each DPP-4 inhibitor on glycemic control; HbA1c levels are decreased by 0 ...
Shin-Ichi, Harashima, Nobuya, Inagaki
openaire +1 more source
Now seven compounds of DPP-4 inhibitor are available in Japan. They can be used in any stage of type 2 diabetes if the insulin secretion capacity is retained; first-line choice to third-line choice or combination with insulin therapy. There is no apparent difference in effect of each DPP-4 inhibitor on glycemic control; HbA1c levels are decreased by 0 ...
Shin-Ichi, Harashima, Nobuya, Inagaki
openaire +1 more source
[Once-weekly DPP-4 inhibitor].
Nihon rinsho. Japanese journal of clinical medicine, 2016Trelagliptin is the first once-weekly dipeptidyl peptidase-4(DPP-4) inhibitor in the world. Trelagliptin inhibits DPP-4 activity with lower drug concentration compared with other once- (or twice-) daily DPP-4 inhibitors in in vitro study. More than 70 % of DPP-4 activity is inhibited even 1 week after administration of trelagliptin administration in ...
Norio, Harada, Nobuya, Inagaki
openaire +1 more source
How safe are DPP‐4 inhibitors?
Practical Diabetes, 2013AbstractAbstract.
Laura McCreight, Miles Fisher
openaire +1 more source
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
Archives of Pharmacal Research, 2016Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are an emerging class of antidiabetic drugs that constitutes approximately fifty percent of the market share of the oral hypoglycemic drugs. Its mechanism of action for lowering blood glucose is essentially via inhibition of the rapid degradation of incretin hormones, such as glucagon-like peptide ...
openaire +2 more sources
Cardiovascular safety and DPP‐4 inhibitors
Practical Diabetes, 2013Abstract Following the rosiglitazone controversy there is a requirement from the licensing agencies that new antidiabetic drugs must be shown not to increase cardiovascular risk during phase 3 development. This includes studying patients with high cardiovascular risk, who were previously excluded from phase 3 studies.
David M Carty +2 more
openaire +1 more source
DPP-4 inhibitors: pharmacological differences and their clinical implications
Expert Opinion on Drug Safety, 2014Recently, incretin-based therapy was introduced for the treatment of type 2 diabetes (T2D). In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D.An extensive literature search was performed to analyze the pharmacological ...
Ceriello A +3 more
openaire +2 more sources